Gupta A K, Shear N H
Department of Medicine, Sunnybrook Health Science Center and the University of Toronto, Canada.
J Eur Acad Dermatol Venereol. 1999 Jul;13(1):1-13.
To review the use of the new oral antifungal agents, itraconazole, terbinafine and fluconazole for the treatment of onychomycosis of the toenails.
Until about 10 years ago the two oral agents available to treat onychomycosis were griseofulvin and ketoconazole. Since then the new oral antifungal agents have superseded the traditional oral agents for the management of toenail onychomycosis.
Literature review.
Itraconazole, terbinafine and fluconazole have been used approximately 100 million times to treat superficial mycoses. These agents are more effective than the traditional antimycotics for the treatment of pedal onychomycosis; furthermore, the new agents have a broader spectrum of action than griseofulvin. In general, itraconazole, terbinafine and fluconazole have a favorable adverse-effects profile with drug interactions that are usually predictable and manageable. The new oral antifungal agents have a high benefit-to-risk ratio when used to treat toenail onychomycosis.
回顾新型口服抗真菌药伊曲康唑、特比萘芬和氟康唑在治疗趾甲癣中的应用。
直到大约10年前，可用于治疗甲癣的两种口服药物是灰黄霉素和酮康唑。从那时起，新型口服抗真菌药已取代传统口服药物用于治疗趾甲癣。
文献综述。
伊曲康唑、特比萘芬和氟康唑已被用于治疗浅表真菌病约1亿次。这些药物在治疗足趾甲癣方面比传统抗真菌药更有效；此外，新型药物的抗菌谱比灰黄霉素更广。一般来说，伊曲康唑、特比萘芬和氟康唑的不良反应较轻，药物相互作用通常是可预测和可控制的。新型口服抗真菌药用于治疗趾甲癣时具有较高的效益风险比。
Zotero 插件